Oval Medical Technologies Ltd.
Oval aims to bring truly patient-centric autoinjector platforms to market. Founded in 2009 by Matthew Young, Oval takes a different approach, designing from the outside in, ensuring that all patient needs are met. Our team has a wide range of expertise allowing us to deliver the best solutions to partners and patients. Our business has developed to meet modern quality standards, with a quality system compliant to BS EN 13485:2016, and working to the guidelines and principals from FDA 21 CFR Pt 820, Medical Device Directive 93/42/EEC and ANSI/AAMI HE75. In December 2016, Oval was acquired by SMC Ltd., a global contract manufacturer of finished medical devices.
Oval’s approach to device development combines a deep understanding of patient need with our advanced autoinjector technology, allowing us to customise our platforms and create devices that work for any patient or formulation.
For a truly seamless process, your customised Oval device can be manufactured by our parent company, SMC Ltd., a world-class contract manufacturing company for pharmaceutical, diagnostic and medical devices. With over 700,000 sq. ft. dedicated to medical manufacturing, SMC provides full product services including: program management, tooling, moulded components, automation, clinical manufacturing, and commercial scale manufacturing.
Oval’s devices are designed for manufacturability and ease of assembly from the outset, allowing scalable production to be achieved using manual or automated methods.
Oval’s primary containers are designed for use with conventional fill-finish technologies. Pre-sterilised nest and tub 'ready-to-fill' packaging running on PFS/cartridge fillers available from most major manufacturers, can be utilized with our proprietary closure element. Container closure can be verified in-line using non-destructive testing techniques delivering a robust new generation of primary container technology.
Oval’s philosophy is to design platforms to be customisable for specific patient needs. Going deeper than the immediate cognitive and physical need when delivering a drug, we look at each patient group’s emotional needs in depth to develop devices that work as part of their lifestyle.
Understanding of a patient group factors heavily in our design of a device. Going further than just relabelling a device for a different drug, our technological platforms allow us to fully customise the user interface of a device to meet the needs of each patient group.